You are here

Article info

Article menu

This article has a correction. Please see:

Download PDFPDF

Case report
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma

Authors

  • Aina Oliver-Caldes Hematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, SpainAmyloidosis and Multiple Myeloma Unit, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Raquel Jiménez Hematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, SpainAmyloidosis and Multiple Myeloma Unit, Hospital Clinic de Barcelona, Barcelona, SpainClinical Trial Unit, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Marta Español-Rego Immunology Department, Hospital Clinic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Maria Teresa Cibeira Hematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, SpainAmyloidosis and Multiple Myeloma Unit, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Valentín Ortiz-Maldonado Hematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Luis F Quintana Amyloidosis and Multiple Myeloma Unit, Hospital Clinic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, SpainGlomerular Disease Unit (CSUR), Nephrology Department, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Paola Castillo Amyloidosis and Multiple Myeloma Unit, Hospital Clinic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, SpainPathology Department, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Francesca Guijarro Hematopathology Unit, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Natalia Tovar Hematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, SpainAmyloidosis and Multiple Myeloma Unit, Hospital Clinic de Barcelona, Barcelona, SpainClinical Trial Unit, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Mercedes Montoro Hematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Daniel Benitez-Ribas Immunology Department, Hospital Clinic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Alex Bataller Hematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • E Azucena González-Navarro Immunology Department, Hospital Clinic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Joan Cid Apheresis Unit, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Miquel Lozano Apheresis Unit, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Lorena Perez-Amill Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Beatriz Martin-Antonio Instituto de Investigación Sanitaria, Fundación Jiménez Díaz, Madrid, Spain PubMed articlesGoogle scholar articles
  • Mari-Pau Mena Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • David F Moreno Hematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, SpainAmyloidosis and Multiple Myeloma Unit, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Luis Gerardo Rodríguez-Lobato Hematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, SpainAmyloidosis and Multiple Myeloma Unit, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Josep Maria Campistol Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, SpainGlomerular Disease Unit (CSUR), Nephrology Department, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Gonzalo Calvo Clinical Pharmacology Department, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Joan Bladé Hematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, SpainAmyloidosis and Multiple Myeloma Unit, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Laura Rosiñol Hematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, SpainAmyloidosis and Multiple Myeloma Unit, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Manel Juan Immunology Department, Hospital Clinic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Mariona Pascal Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Alvaro Urbano-Ispizua Hematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Carlos Fernández de Larrea Hematology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, SpainAmyloidosis and Multiple Myeloma Unit, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Carlos Fernández de Larrea; CFERNAN1{at}clinic.cat
View Full Text

Citation

Oliver-Caldes A, Jiménez R, Español-Rego M, et al
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma
Journal for ImmunoTherapy of Cancer 2021;9:e003783. doi: 10.1136/jitc-2021-003783

Publication history

  • Accepted November 14, 2021
  • First published December 7, 2021.
Online issue publication 
February 03, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.